evidence based management
play

Barbara Schmidt, MD, MSc, CM Evidence-based management of apnea of prematurity: Is caffeine the magic bullet? B Adams K Barrington P Davis A Golan E Goldsch E Herlenius C Mayes A Ohlsson K Sankaran

0 downloads 3 Views 1,4 MB Size Report
  1. Barbara Schmidt, MD, MSc, CM Evidence-based management of apnea of prematurity: Is caffeine the magic bullet?

  2. B Adams K Barrington P Davis A Golan E Goldsch E Herlenius C Mayes A Ohlsson K Sankaran A Solimano Caffeine for Apnea of Prematurity (CAP) R. Alvaro J Dix N Granke M Lacy D Moddemann R Sauve A Synnes Trial P Anderson K Callanan D Dewey H Halliday H Lagercrantz T Mulder R Regev B Schmidt W Tin S Arnon M Clarke L Doyle AM Hamiltion A Juster-Reicher B Lemyre K O’Brien G Reynolds A Schulze H Walti H-U Bucher L Costantini A Golan R Haslam M Khairy H MacLean G Opie R Roberts E Shinwell A van Wassenaer

  3. CAP Trial Timeline 1998 Formulation of study question 1999-2004 Enrolment of > 2000 infants 2006 Short-term outcomes 2007 Primary outcome at 18 months 2008 Inaugural Trial of the Year Award 2012 Outcomes at 5 years 2017 Outcomes at 11 years

  4. ORIGINAL STUDY QUESTION Among infants with BW 500-1250 g P who are at risk of apnea of prematurity, does the use of caffeine I compared with placebo C O increase the risk of death or neurosensory disability T at a corrected age of 18 months

  5. PATIENT ACCRUAL Europe Canada/US n=434 n=1052 Australia n=520

  6. Short Term Outcomes of the Caffeine Trial Caffeine Placebo Odds Ratio Outcome n/N n/N (95% CI) BPD 350/963 447/954 Severe ROP 49/965 75/955* Brain injury 126/967 138/966 NEC 63/1006 67/1000 PDA drug Tx 293/1001 381/999 PDA surgery 45/1001 126/999 0.2 0.5 1 2 5 NEJM 2006;354:2112 and *2007;357:1893 Favours Caffeine Favours Placebo

  7. 18-Months Outcomes of the Caffeine Trial Caffeine Placebo Odds Ratio Outcome n/N n/N (95% CI) Death or disability 377/937 431/932 Death 62/974 63/970 Cerebral Palsy 40/909 66/901 Cognitive delay 293/867 329/858 Hearing loss 17/909 22/905 Blindness 6/911 8/905 0.2 0.5 1 2 5 N Engl J Med 2007;357:1893 Favours Caffeine Favours Placebo

  8. 2008 SCT/Imp /ImpACT ACT CLINI INICAL CAL TRIAL AL OF THE YEAR R A W ARD Long Term Effects of Caffeine for Apnea of Prematurity Trial PI: Barbara Schmidt, MD, MSc In recognition of a landmark randomized clinical trial to improve the lives of premature infants. Eleanor McFadden, MA Steven Goodman, MD, PhD President, Society for Clinical Trials Project ImpACT

  9. Death or Disability at 5 Years Caffeine Placebo 200 of 807 176 of 833 24.8% 21.1% OR = 0.82 95% CI 0.65-1.03 p = 0.09

  10. Gross Motor Function (GMFCS) Level Caffeine Placebo P-value Normal 91% 86% 0.006 1 7.0% 10.1% 2 0.7% 1.0% 3 0.6% 0.6% 4 0.5% 1.3% 5 0.5% 0.8%

  11. Rates of DCD at 5 Years Caffeine Placebo 106 of 698 83 of 735 15.2% 11.3% OR = 0.70 95% CI 0.51-0.95 p =.024

  12. Study Question Among English or French speaking P CAP trial participants, I does neonatal caffeine therapy C compared with placebo decrease the risk of functional O impairment T at age 11 years?

  13. Primary Outcome at 11 Years Functional impairment-at least 1 of: • Poor academic performance • Motor Impairment • Behavior Problem Tests: Wide Range Achievement Test-4 Movement ABC-2 Child Behavior Checklist - Parent

  14. 1202 CAP children were eligible 602 caffeine 600 placebo 457 463 (76%) (77%) Composite Primary Outcome

  15. Outcomes of 11 Year Cohort at 18 Mo Caffeine Placebo P-value Disability 29.7% 36.4% 0.03 CP 3.8% 7.0% 0.03 MDI < 85 27.8% 31.3% 0.25 MDI < 70 9.7% 12.3% 0.22

  16. Functional Impairment at 11 Years Caffeine Placebo 174 of 463 145 of 457 37.6% 31.7% OR = 0.78 95% CI 0.59-1.02 p = 0.07

  17. Types of Impairments Caffeine Placebo P-value Academic 14.4% 13.2% 0.58 Motor 19.7% 27.5% 0.009 Behavior 10.9% 8.3% 0.22

  18. Types of Impairments Caffeine Placebo P-value Academic 14.4% 13.2% 0.58 Motor 19.7% 27.5% 0.009 Behavior 10.9% 8.3% 0.22 Number Needed to Treat: 13 (95% CI, 8 to 42)

  19. Conclusion I Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor and behavioral impairments at age 11 years. However,

  20. Conclusion II Caffeine therapy reduced the risk of motor impairment 11 years later. At the doses used in the CAP trial, neonatal caffeine therapy is effective and safe into middle school age.

  21. Last Use of Respiratory Support* Caffeine Placebo P value Intubation 29.1 30.0 <0.0001 Any pos. 31.0 32.0 <0.0001 pressure Oxygen 33.6 35.1 <0.0001 * Median Postmenstrual Age

  22. Explaining the benefit of caffeine PMA at last use of any positive airway pressure (mean, 31.4 weeks caffeine; 32.8 weeks placebo) explained 53% (95% CI, 22-100%) of the benefit of caffeine on motor impairment 11 years later.

  23. Explaining the benefit of caffeine “Caffeine likely is not a direct brain or a lung drug but rather a drug that decreases adverse effects of interventions to treat apnea”. Alan Jobe, AJRCCM 2017

  24. PEDIATRICS 2016: 137;e20

  25. AAP Conclusion Caffeine citrate is a safe and effective treatment of apnea of prematurity when administered at • 20 mg/kg loading dose • 5 to 10 mg/kg per day maintenance

  26. Beware of risky treatment creep 1. Indication: Apnea of prematurity 2. Dose: More is not always better 3. Timing: How early is too early? In the CAP trial, the median age at start of drug therapy was 3 days.

  27. CAP Children + Families Neonatal Trials Group McMaster University Investigators + staff in Canada Australia United Kingdom Sweden Canadian Institutes of Health Research (CIHR)

Recommend Documents


outcomes and evidence based medicine systematic reviews
Outcomes and Evidence Based Medicine

Outcomes and Evidence Based Medicine Systematic Reviews Management of the

management information system to improve evidence
Management Information System to

Leading with Evidence: Implementing a global Management Information System to

literacy instruction
Literacy Instruction Exemplary

Literacy Instruction Exemplary Practices Evidence-Based Practice Best

knowledge management on evidence based adaptation
Knowledge Management on Evidence-based

Strengthening Capacities Through Research, Training and Knowledge Management

implementing evidence based pph prevention and management
Implementing Evidence-Based PPH

Implementing Evidence-Based PPH Prevention and Management BLAMI DAO

the promise of evidence based policymaking
THE PROMISE OF EVIDENCE-BASED

THE PROMISE OF EVIDENCE-BASED POLICYMAKING Report of the U.S. Commission on

foundations for evidence based
Foundations for Evidence-Based

Foundations for Evidence-Based Policymaking Act of 2018 Evidence Act

available evidence
available evidence Justin Irvine

Using sound science and best available evidence Justin Irvine Evidence based

motivation and incentives an evidence based approach to
Motivation and Incentives: An

Motivation and Incentives: An Evidence-Based Approach to Community Management

evidence based management of meniscal tears
Evidence Based Management of Meniscal

Evidence Based Management of Meniscal Tears Kenneth G. Swan, Jr., MD NO

industrial wind turbines and adverse health effects
Industrial Wind Turbines and Adverse

~n Industrial Wind Turbines and Adverse Health Effects: A Madison County, Iowa

sleep disorders oral presentation project
Sleep Disorders Oral Presentation

Sleep Disorders Oral Presentation Project 1. Choose a topic to research: You

disqualifying medical issues
DISQUALIFYING MEDICAL ISSUES THE MOST

DISQUALIFYING MEDICAL ISSUES THE MOST COMMON THINGS THAT CAUSE PROBLEMS FOR

disability law and reasonable accommodation
Disability Law and Reasonable

Disability Law and Reasonable Accommodation Mark Maxin, Esq. OPM Roundtable

welcome you
Welcome You Bronze Sponsors:

2020 NRTRC TAO VIRTUAL CONFERENCE Northwest Regional Telehealth Resource

developmental feeding
Developmental Feeding Considerations

Developmental Feeding Considerations for Acute and Critical Neonatal Care

ssm health weight management services
SSM Health Weight Management Services

SSM Health Weight Management Services Metabolic and Bariatric Surgery

u s department of veterans affairs
U.S. Department of Veterans Affairs

National Academy of Sciences, Engineering, and Medicine (NASEMs) Committee on

investigational drug steering committee team science
Investigational Drug Steering Committee

Investigational Drug Steering Committee Team Science Meeting 11 Jan, 2013 11

arey pphn how to manage mohit sahni
Arey PPHN!!! How to manage? Mohit

Arey PPHN!!! How to manage? Mohit Sahni Consultant Neonatologist, Neonatal

hypertriglyceridemia
Hypertriglyceridemia JANEL LIANE CALA,

Hypertriglyceridemia JANEL LIANE CALA, RPH MEDICAL CENTER HOSPITAL

food is medicine
Food is Medicine Dariush Mozaffarian,

Food is Medicine Dariush Mozaffarian, MD, DrPH Dean Jean Mayer Professor of